Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.73 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bifluranol SCHEMBL29928815 | 1.00 | SHBG (0.73) | SHBGCYP17A1ALOX15ESR1SLC6A3 | |
| Bifluranol SCHEMBL1650515 | 1.00 | SHBG (0.73) | SHBGCYP17A1ALOX15ESR1SLC6A3 | |
| Bifluranol SCHEMBL23620730 | 0.94 | SHBG (0.65) | SHBGCYP17A1ALOX15ESR1SLC6A3 | |
| SCHEMBL23620729 | 0.84 | SHBG (0.53) | SHBGCYP17A1ESR1LMNAPTGS1 | |
| SCHEMBL13912410 | 0.84 | SHBG (0.64) | SHBGALOX15ESR1SLC6A3TDP1 | |
| SCHEMBL10946354 | 0.83 | SHBG (0.78) | SHBGCYP17A1ALOX15ESR1SLC6A3 | |
| Pentafluranol SCHEMBL2734658 | 0.82 | SHBG (0.54) | SHBGCYP17A1ALOX15PGRAR | |
| SCHEMBL9908608 | 0.80 | SHBG (0.64) | SHBGCYP17A1ALOX15SLC6A3TDP1 | |
| SCHEMBL5082590 | 0.78 | SHBG (0.66) | SHBGCYP17A1ALOX15ESR1SLC6A3 | |
| SCHEMBL11064607 | 0.77 | SHBG (0.51) | SHBGCYP17A1ALOX15ESR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-11850306-B2 | Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose | UPM-KYMMENE CORPORATION (FI) | 2023-12-26 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| EP-4125828-A1 | ANTI-ANDROGEN OR AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATMENT OF A VIRAL RESPIRATORY INFECTION | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2023-02-08 | — | — | EP | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20210315838-A1 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2021-10-14 | — | — | US | claimed |
| WO-2021202014-A1 | ANTI-ANDROGEN OR AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATMENT OF A VIRAL RESPIRATORY INFECTION | APPLIED BIOLOGY, INC. (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210299209-A1 | SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2021-09-30 | — | — | US | claimed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | SHBG 67/4885CYP17A1 1370/4885ALOX15 359/4885 |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | SHBG 559/4885CYP17A1 2615/4885ALOX15 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.